In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
about
PPARs and the cardiovascular systemUric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?Effects of aging and type 2 diabetes on resting and post occlusive hyperemia of the forearm; the impact of rosiglitazoneThe metabolic vascular syndrome - guide to an individualized treatmentPPAR-γ -- a possible drug target for complicated pregnanciesTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.Human obesity and endothelium-dependent responsivenessInvestigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications.Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.PPAR-γ agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow.Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivityTreating coronary disease and the impact of endothelial dysfunction.Rosiglitazone via PPARγ-dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactone.APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice.Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator.Microvascular responsiveness in obesity: implications for therapeutic intervention.Endothelial dysfunction: cardiovascular risk factors, therapy, and outcomeInsulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.PPAR Agonists and Cardiovascular Disease in Diabetes.Different impacts of metabolic syndrome components on insulin resistance in type 2 diabetes.The vascular endothelium in diabetes--a therapeutic target?Nitric oxide-dependent endothelial function and cardiovascular disease.Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cellsPeroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectivesMetformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Effect of Endomorphins on HUVECs Treated by ox-LDL and Its Related Mechanisms.The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.Review of approved pioglitazone combinations for type 2 diabetes.Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease.Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.
P2860
Q24642728-090BEC91-5846-4C34-ACD5-54328A4AAF35Q24678615-3736D0FF-B0E2-4139-B6E5-8FF95E1BD95AQ24792848-D7C67A18-860F-4024-9CD1-62FCF3AA6BEAQ26767142-7D554DF6-7950-4F54-BD3A-D90031EC9536Q26863678-A37F2DC2-21EE-4D82-B59B-37EBD548CABBQ27007027-A5BB6622-F042-4A27-BEB8-85CB9BC9721BQ27021665-9CD21650-EB84-4295-97E8-F41C98F2F3DFQ33380278-AAAD6D9A-86B3-48A9-BDAB-54C846B3041DQ33575808-93C93029-AF28-4253-B37A-D105C0F1659AQ33654306-1F12F5C8-0CEC-4DB3-A529-8B5B3BEBA6F4Q33776230-5224F326-6972-4C15-B6D2-496D5DEC0DE3Q33880303-4BFC8941-3BD4-46C2-88FE-B871A8443D56Q33901576-0B819191-17D2-480F-9090-95AD0B3500CEQ34594675-3940C48C-E4E2-46AD-99B5-9830A8D7BFEEQ34624984-8C31FE6A-0F79-4F20-A385-9281A892C008Q34774079-C60FE6BF-E4DD-460F-ACDF-833F5504342EQ35039274-819CD6B9-31A5-4AF6-A448-2FC9A6865544Q35190437-D64C5F25-0512-48C5-A063-D6058968865FQ35196366-A0BD843D-0FC1-4E38-8A0F-01B292AB3F46Q35391044-9B2C0491-9E0D-457F-B72B-77CE48AF2699Q35405338-280AD6AE-F31F-4EFD-930E-630BBCA88658Q35784092-7AE1C671-326C-41D0-8E7E-262D369859E3Q35791764-9DB462DA-6D96-41A1-B95E-BCCAF0404BFFQ35859728-3D0B3EE3-E5B7-4F41-B34A-DF9809273FEDQ36012867-EEEF51F4-A439-4CF9-8A5C-C37D311DC597Q36381003-A060F45D-14FE-4550-B530-9B4D0CE4E651Q36444975-AE5BBD23-CBA4-443D-ACE3-937C39BAA9DEQ36610550-7554DEB8-48AD-4D5C-8050-ABD334285502Q36673550-4BE26438-8D3C-40AB-BBBF-E493319BF2FEQ36745654-468DD6DF-56AC-4CF1-A4AD-5A4B1BE49A25Q36777447-C8A9AE97-6797-4742-8984-3D2928156883Q36812788-4A843E70-D62D-4E9F-A8D5-3C01223857DBQ36847318-C6569AD4-FD57-4196-96F7-5A7D1C62FD38Q36892489-BE79C9B7-3AF3-4A0D-A8F0-777B8EB03D83Q37107490-BFBF17BE-31B7-468C-9B0A-9D9DA9C569BFQ37184611-0B9157E4-C8E0-4F15-A689-80AAF3DB5966Q37395321-BABDB574-6D1D-48A5-A18C-0CBAA0157D88Q37884618-907B7CF9-6670-420E-A647-868E72AAE2B9Q37943863-661D8D52-720F-4118-AB55-2132B14D7726Q37957629-66670C15-B90F-41A0-9205-22027F48266F
P2860
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
In type 2 diabetes, rosiglitaz ...... ndependent of glucose control.
@en
In type 2 diabetes, rosiglitaz ...... ndependent of glucose control.
@nl
type
label
In type 2 diabetes, rosiglitaz ...... ndependent of glucose control.
@en
In type 2 diabetes, rosiglitaz ...... ndependent of glucose control.
@nl
prefLabel
In type 2 diabetes, rosiglitaz ...... ndependent of glucose control.
@en
In type 2 diabetes, rosiglitaz ...... ndependent of glucose control.
@nl
P2093
P921
P356
P1433
P1476
In type 2 diabetes, rosiglitaz ...... ndependent of glucose control.
@en
P2093
Frank Pistrosch
Jens Passauer
Katja Fuecker
Peter Gross
Sabine Fischer
P304
P356
10.2337/DIACARE.27.2.484
P407
P577
2004-02-01T00:00:00Z